File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion

TitleA prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion
Authors
KeywordsLetrozole pretreatment
Misoprostol
Second-trimester medical abortion
Issue Date2011
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraception
Citation
Contraception, 2011, v. 84 n. 6, p. 628-633 How to Cite?
AbstractBackground: The aim of this randomized trial was to evaluate the abortion rate of combined regimen of letrozole and misoprostol in second-trimester abortion. Study Design: This was a randomized, double-blinded, placebo-controlled trial of 130 women requesting legal termination of pregnancy at gestational age between 12 and 20 weeks. Letrozole 7.5 mg or placebo were given for 3 days, followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses on the third day. Results: The abortion rate in 24 and 48 h were similar for the letrozole and placebo groups (24 h: 93.8% vs. 90.8%, respectively, p=.718; 48 h: 98.5% vs. 95.4%, respectively, p=.496). The median induction-to-abortion interval was also similar for the letrozole and placebo groups (9.6 h vs. 10.6 h, p=.145). All the side effects were comparable between the two groups. Conclusion: The use of letrozole pretreatment (7.5 mg daily for 3 days) with misoprostol in second-trimester abortion does not significantly improve the abortion rate of the misoprostol-only regimen. © 2011 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/152949
ISSN
2015 Impact Factor: 2.788
2015 SCImago Journal Rankings: 1.557
ISI Accession Number ID
Funding AgencyGrant Number
University of Hong Kong200707176068
Funding Information:

We thank all women who participated in this study and Ms. Jane Chan for the coordination of the study. This study was funded by Small Project Funding of the University of Hong Kong (200707176068).

References

 

DC FieldValueLanguage
dc.contributor.authorLee, VCYen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2012-07-16T09:52:56Z-
dc.date.available2012-07-16T09:52:56Z-
dc.date.issued2011en_HK
dc.identifier.citationContraception, 2011, v. 84 n. 6, p. 628-633en_HK
dc.identifier.issn0010-7824en_HK
dc.identifier.urihttp://hdl.handle.net/10722/152949-
dc.description.abstractBackground: The aim of this randomized trial was to evaluate the abortion rate of combined regimen of letrozole and misoprostol in second-trimester abortion. Study Design: This was a randomized, double-blinded, placebo-controlled trial of 130 women requesting legal termination of pregnancy at gestational age between 12 and 20 weeks. Letrozole 7.5 mg or placebo were given for 3 days, followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses on the third day. Results: The abortion rate in 24 and 48 h were similar for the letrozole and placebo groups (24 h: 93.8% vs. 90.8%, respectively, p=.718; 48 h: 98.5% vs. 95.4%, respectively, p=.496). The median induction-to-abortion interval was also similar for the letrozole and placebo groups (9.6 h vs. 10.6 h, p=.145). All the side effects were comparable between the two groups. Conclusion: The use of letrozole pretreatment (7.5 mg daily for 3 days) with misoprostol in second-trimester abortion does not significantly improve the abortion rate of the misoprostol-only regimen. © 2011 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraceptionen_HK
dc.relation.ispartofContraceptionen_HK
dc.subjectLetrozole pretreatmenten_HK
dc.subjectMisoprostolen_HK
dc.subjectSecond-trimester medical abortionen_HK
dc.titleA prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortionen_HK
dc.typeArticleen_HK
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.contraception.2011.03.012en_HK
dc.identifier.pmid22078193-
dc.identifier.scopuseid_2-s2.0-81155134751en_HK
dc.identifier.hkuros201407en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81155134751&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume84en_HK
dc.identifier.issue6en_HK
dc.identifier.spage628en_HK
dc.identifier.epage633en_HK
dc.identifier.isiWOS:000297714100014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLee, VCY=35758969300en_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK
dc.identifier.citeulike9274304-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats